EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 Julho 2023 - 8:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical
company committed to developing and commercializing therapeutics to
help improve the lives of patients with serious eye disorders,
today announced that the Company granted non-statutory stock
options to new employees as inducement awards outside the Company’s
2023 Long-Term Incentive Plan in accordance with NASDAQ Listing
Rule 5635(c)(4).
The Company granted stock options to purchase up
to an aggregate of 14,000 shares of EyePoint Pharmaceuticals common
stock to two new employees. The stock options were granted on July
14, 2023. The grants were approved by the Compensation Committee
and made as an inducement material to each employee entering into
employment with EyePoint Pharmaceuticals in accordance with NASDAQ
Listing Rule 5635(c)(4). The option awards have an exercise price
of $10.97 per share, the closing price of EyePoint Pharmaceuticals’
common stock on July 14, 2023. The options have a ten-year term and
vest over four years, with 25% of the original number of shares
vesting on the first anniversary of the applicable employee’s date
of grant and the remainder vesting in equal monthly installments
over the following three years. Vesting of the options is subject
to the employee’s continued service with EyePoint Pharmaceuticals
through the applicable vesting dates.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
company committed to developing and commercializing therapeutics to
help improve the lives of patients with serious eye disorders. The
Company's pipeline leverages its proprietary bioerodible Durasert
E™ technology for sustained intraocular drug delivery including
EYP-1901, an investigational sustained delivery intravitreal
anti-VEGF treatment currently in Phase 2 clinical trials. The
proven Durasert® drug delivery platform has been safely
administered to thousands of patients' eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts. For more information visit
www.eyepointpharma.com.
For EyePoint Pharmaceuticals:
Investors:Christina TartagliaStern
IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media Contact:Amy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024